Tag: influenza vacines division
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
Why manufacturers are embracing AI-powered smart supply chains
Manufacturers are facing an increasingly volatile environment, where rapid changes in demand, supply chain disruptions, and continued cost pressures are transforming the way products are planned, made, and delivered.
